CEO to Provide Corporate Update on Late- and Mid-Stage Programs
Focused on Acute Myeloid Leukemia and Other Advanced Cancers
NEW YORK--(BUSINESS WIRE)--
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the
Company"), a biopharmaceutical company developing innovative targeted
payload immunotherapeutics for the treatment of advanced cancers, today
announced that Dr. Kaushik J. Dave, President and CEO of Actinium, will
present at the Canaccord Genuity 34th Annual Growth
Conference on Wednesday, August 13, 2014, at 9:30 a.m. ET in Boston, MA.
The Company's presentation is scheduled to begin at 9:30 a.m. ET and
will be available via a live webcast. To access the live audio webcast,
please log on through a link located in the Investors section of
Actinium's website at www.actiniumpharma.com
under the Corporate Presentations tab. A replay will be available on the
Actinium website within 48 hours and will be archived for a limited time.
Dr. Dave and other members of the management team will be available for
one-on-one meetings at the conference. Members of the investment
community who are interested in meeting with management should contact
their Canaccord Genuity representative, or Evan Smith, CFA of Actinium
Pharmaceuticals, at 646-840-5442 or firstname.lastname@example.org.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com)
is a New York-based biopharmaceutical company developing innovative
targeted payload immunotherapeutics for the treatment of advanced
cancers. Actinium's targeted radiotherapy is based on its proprietary
delivery platform for the therapeutic utilization of alpha-emitting
actinium-225 and bismuth-213 and certain beta emitting
radiopharmaceuticals in conjunction with monoclonal antibodies. The
Company's lead radiopharmaceutical Iomab™-B will be used in preparing
patients for hematopoietic stem cell transplant, commonly referred to as
bone marrow transplant. The Company is preparing a single, pivotal,
multicenter Phase 3 clinical study of Iomab™-B in refractory and
relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a
primary endpoint of durable complete remission. The Company's second
program, Actimab-A, is continuing its clinical development in a Phase
1/2 trial for newly diagnosed AML patients over the age of 60 in a
single-arm multicenter trial.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements
are based on management's current expectations and involve risks and
uncertainties, which may cause actual results to differ materially from
those set forth in the statements. The forward-looking statements may
include statements regarding product development, product potential, or
financial performance. No forward-looking statement can be guaranteed
and actual results may differ materially from those projected. Actinium
Pharmaceuticals undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Source: Actinium Pharmaceuticals, Inc.